Contract Pharma Manufacturing News

  1. Dogwood Therapeutics Announces Worldwide Development And Commercialization Partnership For Anti-Viral Assets With Potential Value Up To $100M 4/23/2026

    Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy, today announced a global development and commercialization partnership with PRIDCor Therapeutics, LLC (“PRIDCor”), a clinical-stage biopharmaceutical company developing antiviral therapies for infection-associated chronic illnesses including Long-COVID, for Dogwood’s anti-viral candidates, IMC-1 and IMC-2.

  2. Omios Biologics And XDemics Corporation Announce Strategic Collaboration To Revolutionize Oncolytic Virus Manufacturing And Accessibility 4/23/2026

    Omios Biologics and XDemics Corporation have entered into a multi-year strategic collaboration to optimize the production of Omios' next-generation oncolytic virus (OV) therapeutics using XDemics' High-Density Cell Respiration (HDCR) bioproduction platform.

  3. Minaris Delivers 100% Manufacturing And Release Success For Chimeric Therapeutics' CDH17 Autologous CAR‑T Program 4/23/2026

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Chimeric Therapeutics (ASX: CHM, “Chimeric” or the “Company”), a leading Australian cell therapy company, today announced a 100% batch manufacturing and release success rate in support of Chimeric Therapeutics’ CDH17-targeted autologous CAR-T program in Phase 1A/1B for gastrointestinal (GI) cancers, including colorectal and gastric cancer as well as neuroendocrine cancers.

  4. Plus Therapeutics Initiates Manufacturing Activities With SpectronRx Under A Master Services Agreement To Support GMP Pivotal Trial Readiness For REYOBIQ™ 4/23/2026

    Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announced today the initiation of manufacturing activities and technology transfer with SpectronRx under a previously executed Master Services Agreement (MSA), in support of late-stage clinical manufacturing of Rhenium-186 and REYOBIQ.

  5. Mikart And Benuvia Announce Strategic Co-Marketing Partnership To Deliver End-To-End Controlled Substance Development And Finished Drug Product Manufacturing Solutions 4/23/2026

    Mikart, LLC ("Mikart"), a leader in formulation development, analytical testing, and finished dose manufacturing, and Benuvia Operations, LLC ("Benuvia"), a CDMO with specialized development and manufacturing experience in controlled substance and complex APIs, today announced a strategic co-marketing partnership.

  6. Aethl Bio And Pure Source Enter Collaboration To Advance Proprietary Hydrogel Product Line 4/22/2026

    Aethl Bio, Inc., an emerging innovator in advanced hydrogel-based platforms, today announced that it has entered a Memorandum of Understanding (MOU) with Pure Source, LLC, an FDA-registered contract manufacturer headquartered in Doral, Florida.

  7. Jamjoom Pharma Signs Agreement To Acquire Pharmaceutical Manufacturing Facility In Saudi Arabia From Pfizer 4/22/2026

    Jamjoom Pharma, a leading pharmaceutical company in the Middle East and Africa (MEA), today announced the signing of a Facility Sale and Purchase Agreement with Pfizer Saudi Limited Company to acquire a pharmaceutical manufacturing facility located in King Abdullah Economic City (KAEC), Saudi Arabia.

  8. Made Scientific And Regenicin Announce Manufacturing Relationship To Advance NovaDerm Toward FDA Product Approval 4/22/2026

    Made Scientific, Inc., a U.S.-based cell therapy contract development and manufacturing organization (CDMO), and Regenicin, Inc., a biotechnology company specializing in the development and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, today announced a manufacturing relationship to advance NovaDerm, an autologous cultured skin substitute for severe burns and chronic wounds, toward a U.S. FDA Orphan product approval.

  9. OrganaBio And RxMP Therapeutics Announce Manufacturing Partnership To Advance RMP-402 Hemostatic Drug Product 4/22/2026

    OrganaBio, LLC ("OrganaBio"), a vertically integrated blood and cell products and services company delivering end-to-end solutions for cell and gene therapy developers, and RxMP Therapeutics, Inc. ("RxMP"), a late pre-clinical development stage therapeutics company developing novel therapies for the rapid control of severe hemorrhage, today announced a manufacturing partnership under which OrganaBio will serve as RxMP's contract manufacturing partner for the cGMP production of its lead product candidate, RMP-402.

  10. Oribiotech, Cell Therapies And AdAlta Join Forces To Tackle Cell Therapy Manufacturing Challenges 4/21/2026

    AdAlta Limited (“AdAlta” or “the Company”), Oribiotech Ltd (“Ori”) and Cell Therapies Pty Ltd (“CTPL”) have signed a Memorandum of Understanding (“MoU”) to bring Ori’s next-generation automated cell therapy manufacturing platform, IRO, to AdAlta’s pipeline and more broadly to cell therapy researchers and developers in Australia and Asia Pacific.